Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Norbert Tennagels & Ulrich Werner. (2013) The metabolic and mitogenic properties of basal insulin analogues. Archives of Physiology and Biochemistry 119:1, pages 1-14.
Read now
Read now
Jingxuan Pan, Chun Chen, Yanli Jin, Enrique Fuentes-Mattei, Guermarie Velazquez-Tores, Juliana Maria Benito, Marina Konopleva, Michael Andreeff, Mong-Hong Lee & Sai-Ching J. Yeung. (2012) Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle 11:12, pages 2314-2326.
Read now
Read now
George Dailey. (2011) Rapid-acting insulin glulisine: an update on clinical experience. Expert Review of Endocrinology & Metabolism 6:4, pages 527-542.
Read now
Read now
Rickard Ljung, Mats Talbäck, Bengt Haglund, Junmei Miao Jonasson, Soffia Gudbjörnsdòttir & Gunnar Steineck. (2011) Insulin glargine use and short-term incidence of malignancies — a three-year population-based observation. Acta Oncologica 50:5, pages 685-693.
Read now
Read now
Haim Werner, Doron Weinstein, Einat Yehezkel & Zvi Laron. (2011) Controversies in the use of insulin analogues. Expert Opinion on Biological Therapy 11:2, pages 199-209.
Read now
Read now
Doris Mayer & Ernst Chantelau. (2010) Treatment with insulin glargine (Lantus®) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Archives of Physiology and Biochemistry 116:2, pages 73-78.
Read now
Read now
Ashish Shukla, Harald Enzmann & Doris Mayer. (2009) Proliferative effect of Apidra® (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells. Archives of Physiology and Biochemistry 115:3, pages 119-126.
Read now
Read now
Articles from other publishers (53)
Rui-yuan Jiang, Zi-ru Fang, Huan-ping Zhang, Jun-yao Xu, Jia-yu Zhu, Ke-yu Chen, Wei Wang, Xiao Jiang & Xiao-jia Wang. (2023) Ginsenosides: changing the basic hallmarks of cancer cells to achieve the purpose of treating breast cancer. Chinese Medicine 18:1.
Crossref
Crossref
Stéphanie Larose, Christopher Filliter, Robert W. Platt, Oriana H. Y. Yu & Kristian B. Filion. (2023) Long‐acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population‐based cohort study. Diabetes, Obesity and Metabolism 25:8, pages 2279-2289.
Crossref
Crossref
Konrad Sosnowski, Piotr Nehring & Adam Przybyłkowski. (2022) Pancreas and Adverse Drug Reactions: A Literature Review. Drug Safety 45:9, pages 929-939.
Crossref
Crossref
Handan Akil, Jamie Burgess, Sarah Nevitt, Simon P. Harding, Uazman Alam & Philip Burgess. (2021) Early Worsening of Retinopathy in Type 1 and Type 2 Diabetes After Rapid Improvement in Glycaemic Control: A Systematic Review. Diabetes Therapy 13:1, pages 1-23.
Crossref
Crossref
Marie C. Bradley, Yoganand Chillarige, Hana Lee, Xiyuan Wu, Shruti Parulekar, Michael Wernecke, Patricia Bright, Mat Soukup, Thomas E. MaCurdy, Jeffrey A. Kelman & David J. Graham. (2020) Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins. Diabetes Care 43:4, pages 785-792.
Crossref
Crossref
Riccardo Vigneri & Laura Sciacca. 2020. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
377
410
.
Xiaoli Sheng, Kannan Yao, Anwen Shao, Sheng Tu, Xinxia Zhang, Ting Chen & Dingguo Yao. (2019) The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling. Frontiers in Endocrinology 10.
Crossref
Crossref
Klaus Lindauer, Thomas Bartels, Petra Scherer & Mostafa Kabiri. (2019) Development and Validation of an Image Analysis System for the Measurement of Cell Proliferation in Mammary Glands of Rats. Toxicologic Pathology 47:5, pages 634-644.
Crossref
Crossref
Stephen C. Bain, Michael A. Klufas, Allen Ho & David R. Matthews. (2019) Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes, Obesity and Metabolism 21:3, pages 454-466.
Crossref
Crossref
Riccardo Vigneri & Laura Sciacca. 2019. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
1
34
.
Ramesh Pothuraju, Satyanarayana Rachagani, Wade M. Junker, Sanjib Chaudhary, Viswanathan Saraswathi, Sukhwinder Kaur & Surinder K. Batra. (2018) Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Crossref
Ayush Sharma & Suresh T. Chari. (2018) Pancreatic Cancer and Diabetes Mellitus. Current Treatment Options in Gastroenterology 16:4, pages 466-478.
Crossref
Crossref
Riccardo Vigneri & Laura Sciacca. 2018. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
377
410
.
Riccardo Vigneri & Laura Sciacca. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
34
.
Jennifer W. WuLaurent AzoulayAgnieszka MajdanJean-François BoivinMichael PollakSamy Suissa. (2017) Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. Journal of Clinical Oncology 35:32, pages 3647-3653.
Crossref
Crossref
Antonino Belfiore, Roberta Malaguarnera, Veronica Vella, Michael C Lawrence, Laura Sciacca, Francesco Frasca, Andrea Morrione & Riccardo Vigneri. (2017) Insulin Receptor Isoforms in Physiology and Disease: An Updated View. Endocrine Reviews 38:5, pages 379-431.
Crossref
Crossref
Adi J. Klil-Drori, Laurent Azoulay & Michael N. Pollak. (2016) Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?. Nature Reviews Clinical Oncology 14:2, pages 85-99.
Crossref
Crossref
Christoph Hasslacher, Felix Kulozik & Justo Lorenzo Bermejo. (2016) Treatment with insulin analogs, especially Glargine and Lispro, associates with better renal function and higher hemoglobin levels in Type 1 diabetic patients with impaired kidney function. Therapeutic Advances in Endocrinology and Metabolism 7:4, pages 166-177.
Crossref
Crossref
Vijay Anand, Shalini Jaswal, Surender Singh, Sudarshan Kumar, Manoj Kumar Jena, Arvind Kumar Verma, Munna Lal Yadav, Jagadeesh Janjanam, Masoud Lotfan, Dhruba Malakar, Ajay Kumar Dang, Tushar Kumar Mohanty, Jai Kumar Kaushik & Ashok Kumar Mohanty. (2015) Functional characterization of Mammary Gland Protein-40, a chitinase-like glycoprotein expressed during mammary gland apoptosis. Apoptosis 21:2, pages 209-224.
Crossref
Crossref
Heleen K Bronsveld, Bas ter Braak, Øystein Karlstad, Peter Vestergaard, Jakob Starup-Linde, Marloes T Bazelier, Marie L De Bruin, Anthonius de Boer, Christine L E Siezen, Bob van de Water, Jan Willem van der Laan & Marjanka K Schmidt. (2015) Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Research 17:1.
Crossref
Crossref
Ivona Baricevic, David R. Jones, Darren L. Roberts, Anne Lutzen, Anders Lundby, Jesper Worm, Bo F. Hansen & Andrew G. Renehan. (2015)
A framework for the
in vitro
evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues
. Carcinogenesis 36:9, pages 1040-1050.
Crossref
Crossref
Jen-Chieh Lin, Wen-Yi Shau & Mei-Shu Lai. (2014) Long-acting Insulin Analogues and Diabetic Retinopathy: A Retrospective Cohort Study. Clinical Therapeutics 36:9, pages 1255-1268.
Crossref
Crossref
B. ter Braak, C. L. E. Siezen, N. Kannegieter, E. Koedoot, B. van de Water & J. W. van der Laan. (2014) Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel. Archives of Toxicology 88:4, pages 953-966.
Crossref
Crossref
Lamiae Grimaldi-Bensouda, David CameronMichel Marty, Anthony H. BarnettFrédérique Penault-Llorca, Michael Pollak, Bernard Charbonnel, Matthew Riddle, Laurent Mignot, Jean-François Boivin, Artak KhachatryanMichel Rossignol, Jacques Bénichou, Annick Alpérovitch & Lucien Abenhaim. (2014) Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study. Diabetes Care 37:1, pages 134-143.
Crossref
Crossref
N. Tennagels, S. Welte, M. Hofmann, P. Brenk, R. Schmidt & U. Werner. (2013) Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats. Diabetologia 56:8, pages 1826-1834.
Crossref
Crossref
Rosalyn D. Ferguson, Emily J. Gallagher, Eyal J. Scheinman, Rawan Damouni & Derek LeRoith. 2013. Hormones and Breast Cancer. Hormones and Breast Cancer
51
98
.
A. J. Varewijck & J. A. M. J. L. Janssen. (2012) Insulin and its analogues and their affinities for the IGF1 receptor. Endocrine Related Cancer 19:5, pages F63-F75.
Crossref
Crossref
Vinay Bhaskar, Ira D. Goldfine, Daniel H. Bedinger, Angela Lau, Hua F. Kuan, Lisa M. Gross, Masahisa Handa, Betty A. Maddux, Susan R. Watson, Shirley Zhu, Ajay J. Narasimha, Raphael Levy, Lynn Webster, Sujeewa D. Wijesuriya, Naichi Liu, Xiaorong Wu, David Chemla-Vogel, Catarina Tran, Steve R. Lee, Steve Wong, Diane Wilcock, Mark L. White & John A. Corbin. (2012) A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control. Diabetes 61:5, pages 1263-1271.
Crossref
Crossref
Sandra Reichstetter, Gerardo M. Castillo, ManShun Lai, Akiko Nishimoto-Ashfield, Aryamitra Banerjee, Alexei Bogdanov, Alexander V. Lyubimov & Elijah M. Bolotin. (2011) Protected Graft Copolymer (PGC) Basal Formulation of Insulin as Potentially Safer Alternative to Lantus® (Insulin-Glargine): A Streptozotocin-Induced, Diabetic Sprague Dawley Rats Study. Pharmaceutical Research 29:4, pages 1033-1039.
Crossref
Crossref
Peter Mayer, Ulrich Reitzenstein, Mareille Warnken, Harald Enzmann & Kurt Racké. (2012) Insulin action on H292 bronchial carcinoma cells as compared to normal bronchial epithelial cells. Pulmonary Pharmacology & Therapeutics 25:1, pages 104-114.
Crossref
Crossref
R. Ruiter, L. E. Visser, M. P. P. van Herk-Sukel, J. W. W. Coebergh, H. R. Haak, P. H. Geelhoed-Duijvestijn, S. M. J. M. Straus, R. M. C. Herings & B. H. Ch. Stricker. (2011) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55:1, pages 51-62.
Crossref
Crossref
Rosalyn D. Ferguson & Derek LeRoith. 2012. Insulin-like Growth Factors and Cancer. Insulin-like Growth Factors and Cancer
37
72
.
Haim Werner & Ernst A Chantelau. (2011) Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years. Diabetology & Metabolic Syndrome 3:1.
Crossref
Crossref
Antonino Belfiore & Roberta Malaguarnera. (2011) Insulin receptor and cancer. Endocrine-Related Cancer 18:4, pages R125-R147.
Crossref
Crossref
S. Liu, Y. Li, T. Lin, X. Fan, Y. Liang & U. Heemann. (2011) High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Research and Clinical Practice 91:2, pages 177-182.
Crossref
Crossref
Grace Sun & Sangeeta R. Kashyap. (2011) Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic Considerations. Journal of Nutrition and Metabolism 2011, pages 1-11.
Crossref
Crossref
Leslie K. Dawson & Leslie A. Hamilton. (2010) Risk of cancer in patients receiving insulin glargine. American Journal of Health-System Pharmacy 67:23, pages 2025-2031.
Crossref
Crossref
M. Shawn McFarland & Rebecca Cripps. (2012) Diabetes Mellitus and Increased Risk of Cancer: Focus on Metformin and the Insulin Analogs. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30:11, pages 1159-1178.
Crossref
Crossref
Nelson B. Phillips, Zhu-li Wan, Linda Whittaker, Shi-Quan Hu, Kun Huang, Qing-xin Hua, Jonathan Whittaker, Faramarz Ismail-Beigi & Michael A. Weiss. (2010) Supramolecular Protein Engineering. Journal of Biological Chemistry 285:16, pages 11755-11759.
Crossref
Crossref
B. Martín-Castillo, A. Vázquez-Martín, C. Oliveras-Ferraros & J.A. Menéndez. (2010) Metformin: a pharmacological approach integrating hyperinsulinemia breast cáncer at the molecular, cellular clinical levels. Avances en Diabetología 26:2, pages 79-94.
Crossref
Crossref
Dara Cannata, Yvonne Fierz, Archana Vijayakumar & Derek LeRoith. (2010) Type 2 Diabetes and Cancer: What Is the Connection?. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:2, pages 197-213.
Crossref
Crossref
C. Kazda, L. Slieker, L. Ilag, R. Byrd, T. Rees & M. Prince. (2010)
Appraising the mitogenicity of insulin analogues relative to human insulin—response to: Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF‐I‐like mitogenic and anti‐apoptotic activity in cultured cancer cells.
Diabetes Metab Res Rev
2009; 25(1): 41–9
. Diabetes/Metabolism Research and Reviews 26:3, pages 145-149.
Crossref
Crossref
Masahiko Sugimoto, Mikio Sasoh, Masashi Ido, Chisato Narushima & Yukitaka Uji. (2010) Retinal Nerve Fiber Layer Decrease during Glycemic Control in Type 2 Diabetes. Journal of Ophthalmology 2010, pages 1-6.
Crossref
Crossref
Antonino Belfiore, Francesco Frasca, Giuseppe Pandini, Laura Sciacca & Riccardo Vigneri. (2009) Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease. Endocrine Reviews 30:6, pages 586-623.
Crossref
Crossref
G. A. Thomson & R. Craig. (2009) Where now for insulin glargine - a time for pragmatic medicine?. International Journal of Clinical Practice 63:10, pages 1413-1415.
Crossref
Crossref
S. Sadikot, A. Sosale, A. Nigam, J. Ahmed, S. Singh, A. Zargar, A. Misra, K. PrasannaKumar, S. Wangnoo, B. Makker, S. Bajaj, J. Singh, U. Dhruv, M. Jali, N. Sinha, K. Sai, Y. SadasivRao, S. Murthy & A. Reddy. (2009) No “Barge in” on “Glargine”!. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 3:3, pages 132-138.
Crossref
Crossref
H. M. Colhoun. (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:9, pages 1755-1765.
Crossref
Crossref
J. M. Jonasson, R. Ljung, M. Talbäck, B. Haglund, S. Gudbjörnsdòttir & G. Steineck. (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 52:9, pages 1745-1754.
Crossref
Crossref
L. G. Hemkens, U. Grouven, R. Bender, C. Günster, S. Gutschmidt, G. W. Selke & P. T. Sawicki. (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:9, pages 1732-1744.
Crossref
Crossref
J. Rosenstock, V. Fonseca, J. B. McGill, M. Riddle, J.-P. Hallé, I. Hramiak, P. Johnston & M. Davis. (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 52:9, pages 1778-1788.
Crossref
Crossref
DR Owens, J Rosenstock & GB Bolli. (2009) Insulin glargine and cancer: cause and effect unproven. Practical Diabetes International 26:7, pages 256-257.
Crossref
Crossref
Nicolai Listov‐Saabye, Marianne Blirup Jensen, Benedicte Kiehr, Erik W. Hansen, Jette E. Svendsen, Anders Lundby, Gitte‐Mai Nelander Holm & Martin B. Oleksiewicz. (2009) MCF‐7 human mammary adenocarcinoma cells exhibit augmented responses to human insulin on a collagen IV surface. Journal of Applied Toxicology 29:6, pages 470-477.
Crossref
Crossref
Renzo Cordera, Barbara Salani & Lucia Briatore. (2009) Insulin analogues: fears, facts and fantasies. Diabetes/Metabolism Research and Reviews 25:1, pages 50-51.
Crossref
Crossref